Eli Lilly plans to launch its experimental oral weight-loss drug orforglipron in India, a senior executive said on Thursday, offering an alternative to injectables that many patients in the world’s most populous nation resist.
Orforglipron is part of a new class of GLP-1 drugs that suppress appetite and follow the same pathway targeted by Eli Lilly’s blockbuster tirzepatide, sold globally as the blockbuster Mounjaro for diabetes and Zepbound for weight loss.
The drug has not been launched…

